Avosentan - CAS 290815-26-8
Catalog number:
290815-26-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C23H21N5O5S
Molecular Weight:
479.51
COA:
Inquire
Targets:
Endothelin Receptor
Description:
Avosentan, also known as SPP301, R-639, and RO 67-0565, is a potent and selective endothelin receptor(ETA receptor) antagonist.
Publictions citing BOC Sciences Products
  • >> More
Purity:
95%
Appearance:
Solid powder
Synonyms:
N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide;Avosentan;290815-26-8;UNII-L94KSX715K;SPP301;Ro67-0565;SPP301
Solubility:
Soluble in DMSO
Storage:
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -41℃ for long term (months to years).
MSDS:
Inquire
Shelf Life:
2 years
Quantity:
Data not available, please inquire.
Boiling Point:
575.472ºC at 760 mmHg
Density:
1.364 g/cm3
InChIKey:
YBWLTKFZAOSWSM-UHFFFAOYSA-N
InChI:
1S/C23H21N5O5S/c1-15-8-9-19(25-14-15)34(29,30)28-22-20(33-18-7-5-4-6-17(18)31-2)23(32-3)27-21(26-22)16-10-12-24-13-11-16/h4-14H,1-3H3,(H,26,27,28)
Canonical SMILES:
CC1=CN=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=CC=NC=C3)OC)OC4=CC=CC=C4OC
1.Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.
Baltatu OC1, Zaugg CE2, Schumacher C3, Louie P3, Campos LA4, Bader M5. Pharmacol Res. 2014 Feb;80:9-13. doi: 10.1016/j.phrs.2013.12.003. Epub 2013 Dec 22.
Multiple studies indicate that endothelin antagonism may have a protective effect for chronic kidney disease. Despite that, clinical studies using avosentan have been halted due to adverse effects including fluid overload. Therefore, we aimed at investigating whether avosentan may have protective effects against hypertensive nephropathy at doses below those inducing fluid-retention. We used double transgenic rats (dTGR), overexpressing both the human renin and angiotensinogen gene, which develop malignant hypertension. Effects of avosentan alone or in combination with low-dose of valsartan (angiotensin AT1 receptor antagonist) on end-organ damage were studied. Avosentan induced a decrease of diuresis (18.3%) with a consequent decrease in hematocrit (8.3%) only at the highest dose investigated (100mg/kg). Treatment with the combination of avosentan and valsartan (10 and 0.1mg/kg, once daily by gavage, respectively) decreased albuminuria to a greater extent than each compound given alone (avosentan: 19.
2.Antidiuretic effects of the endothelin receptor antagonist avosentan.
Baltatu OC1, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA. Front Physiol. 2012 Apr 18;3:103. doi: 10.3389/fphys.2012.00103. eCollection 2012.
Several clinical studies have investigated the potential benefits of endothelin receptor antagonism in chronic pathologies such as diabetic kidney disease. However, fluid retention and edema have been identified as major side effects of endothelin receptor antagonists. In the present study we hypothesized that avosentan which was described as a predominant ET(A) receptor antagonist would produce fluid retention at high concentrations where non-specific blockade of ET(B) receptors may occur. Incremental doses of the predominant ET(A) receptor antagonist SPP301 (0.003; 0.03; 3 mg/kg) were administered intravenously to anesthetized Sprague-Dawley rats undergoing saline diuresis. Diuresis, glomerular filtration rate, and blood pressure (BP) were monitored. SPP301 decreased urine output (5.6; 34.8; 58.8% decrease from vehicle) and fractional excretion of water (5.7; 31.7; 56.4% decrease from vehicle) in a concentration-dependent manner. Glomerular filtration rate was unchanged while BP was reduced by 10 mmHg only by the highest dose of SPP301.
3.Effect of avosentan (SPP-301) in porcine ciliary arteries.
Konieczka K1, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J. Curr Eye Res. 2011 Feb;36(2):118-24. doi: 10.3109/02713683.2010.529982.
PURPOSE: To investigate the vasoactive effect of ET(A)-endothelin receptor antagonists avosentan (SPP-301) and BQ-123 in isolated porcine ciliary arteries with and without endothelium. To investigate the effect of avosentan on the endothelin-1 induced contractions in comparison with BQ-123 and BQ-788 (ET(B)-endothelin receptor antagonist) in isolated porcine ciliary arteries with and without endothelium.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Endothelin Receptor Products


CAS 142375-60-8 FR 139317

FR 139317
(CAS: 142375-60-8)

FR 139317 is a selective Endothelin A receptor antagonist originated by Fujisawa. (Ki values are 1 nM and 7.3 μM at ETA and ETB subtypes respectively). No devel...

CAS 210891-04-6 Edonentan

Edonentan
(CAS: 210891-04-6)

Edonentan, also known as BMS-207940, is a very potent and selective ETA endothelin receptor antagonist (Ki= 10 pM) that shows 80000-fold selective for ETA vs ET...

CAS 157212-55-0 Bosentan Hydrate

Bosentan Hydrate
(CAS: 157212-55-0)

Bosentan inhibits the presser response to big ET-1 both after i.v. and oral administration, with a long duration of action and no intrinsic agonist activity.

CAS 157380-72-8 TAK-044

TAK-044
(CAS: 157380-72-8)

Tak-044 has been found to be an endothelin receptor antagonist that was once studied against some sort of liver disorders and subarachnoid haemorrhage.

CAS 177036-94-1 Ambrisentan

Ambrisentan
(CAS: 177036-94-1)

Ambrisentan, a highly selective antagonist of the endothelin-1 type A receptor with IC50 of 18 nM, is indicated for the treatment of pulmonary arterial hyperten...

CAS 184036-34-8 Sitaxsentan

Sitaxsentan
(CAS: 184036-34-8)

Sitaxsentan, also called as IPI 1040 or TBC 11251, is a potent orally bioactive ET receptor antagonist that has a long duration of action (t1/2, 5–7 hours) and ...

T-0201
(CAS: 169679-53-2)

T-0201 has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied in heart failure and pulmonar...

RO462005
(CAS: 150725-87-4)

RO462005 is an endothelin receptor selective agonist.

CAS 117399-94-7 Endothelin 1 swine, human

Endothelin 1 swine, human
(CAS: 117399-94-7)

Endothelin 1 (swine, human), a vasoconstrictor increased in plasma and explants of patients with uterine leiomyomas, is a synthetic peptide with the sequence of...

Sparsentan
(CAS: 254740-64-2)

Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.

CAS 210421-74-2 Sitaxentan sodium

Sitaxentan sodium
(CAS: 210421-74-2)

Sitaxentan sodium inhibits ET-1-induced stimulation of phosphoinositide turnover with a Ki of 0.69 nM and a pA2 of 8.0.

CAS 186497-07-4 Zibotentan (ZD4054)

Zibotentan (ZD4054)
(CAS: 186497-07-4)

Zibotentan (ZD4054)is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).

A-192621
(CAS: 195529-54-5)

A-192621 is a selective antagonist at endothelin ETB receptor with more effective than IRL-2500 in blocking IRL-1620-induced vasoconstriction, but both augmente...

T-0201 Sodium
(CAS: 188307-16-6)

The sodium salt form of T-0201 which has been found to be an Endothelin A receptor antagonist that could be used as as anti-ischaemic agent and was once studied...

SB-209670
(CAS: 157659-79-5)

SB-209670 has been found to be an endothelin receptor antagonist that was once studied against arrhythmias and hypertension.

N-Despropyl-macitentan
(CAS: 1103522-45-7)

N-Despropyl-macitentan, an active metabolite of Macitentan, is a dual ET receptor antagonist with longer half-life than Macitentan. It has been proved to be eff...

BMS-248360
(CAS: 254737-87-6)

BMS-248360 is a first orally active generation dual action receptor antagonist. BMS-248360 antagonized both Ang II AT1 and endothelin ETA receptors (AT1 IC50 = ...

CAS 180384-56-9 Clazosentan

Clazosentan
(CAS: 180384-56-9)

Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...

CAS 441798-33-0 Macitentan

Macitentan
(CAS: 441798-33-0)

Macitentan is an orally available dual endothelin receptor (ETR) antagonist with potential antihypertensive and antineoplastic activity.

CAS 173937-91-2 Atrasentan

Atrasentan
(CAS: 173937-91-2)

atrasentan hydrochloride is the orally available hydrochloride salt of pyrrolidine-3-carboxylic acid with potential antineoplastic activity. As a selective anta...

Chemical Structure

CAS 290815-26-8 Avosentan

Quick Inquiry

Verification code

Featured Items